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1. Introduction 
Dengue encephalitis and other neurological manifestations of dengue infection have been 
documented with increased frequency since the early 1900’s. Infections with the dengue 
virus present with a wide range of clinical manifestations which have been classified 
according to severity by the World Health Organization (WHO) as; non-specific febrile 
illness, classical dengue syndrome, dengue hemorrhagic fever (DHF) and dengue shock 
syndrome (DSS) (WHO 1997). In 2009, WHO adjustments in the classification of the disease 
resulted in the recognition of two main presentations of dengue. These are referred to as 
Dengue Fever and Severe Dengue. Neurological dengue is classified as a form of Severe 
Dengue (WHO 1997, 2009).  
A member of the Flavivirus genus of the family Flaviviridae, there are 4 genetically and 
antigenically distinct serotypes of dengue (DENV 1–4). Co-circulation of multiple serotypes 
(hyperendemnicity) (Gubler D. 2006), serotype virulence and hyperimmune responses have 
been identified as risk factors for Severe Dengue, an emerging and major public health 
concern in the Americas and the Pacific (Bennett, 2010). The incidence and prevalence of 
dengue encephalitis and other forms of neurological dengue will vary according to the 
degree of endemnicity and epidemic activity of dengue within geographic regions. 
Increased documentation of evidence based dengue encephalitis has accompanied the 
resurgence of dengue infections with the prevalence of dengue encephalitis ranging from 4.2 
% to 13% of central nervous system infections (Solomon et al., 2000 & Jackson, 2008). The 
morbidity and sometimes fatal outcome of dengue encephalitis necessitates a better 
understanding of the disease, early diagnosis and appropriate management. This chapter 
reviews the epidemiology, pathogenesis, clinical features, laboratory diagnosis and evidence 
supporting dengue encephalitis.  
2.Epidemiology 
2.1 Vector and geographic distribution 
Outbreaks of dengue have been documented in the Eastern Mediterranean Region since 
1799 in Egypt. William Smart documented descriptions of neurological manifestations of 
dengue as early as 1827. An example of such documentation is demonstrated in the excerpt 
which follows (Smart, 1877). 
“In children, the attack may be ushered in with convulsions, and the resolution may be 
attended by sensorial depression, approaching more or less to “dementia“, which last 
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condition may attend the stage of resolution of the disease in elderly persons also” (Smart, 
1877). 
By then the disease had earned numerous names including that of “dandy fever” given to it by 
the West Indian negro slaves from the strange attitudes of the sufferers when it first appeared 
among them. It was translated as dengue in Spanish and altered into denguis for scientific 
classification (Smart, 1877, Thomas, 1880). J Thomas also described other names given to this 
disease of wide clinical presentations including: "break-bone fever," "el dengue," which means 
literally "affectation," denguis, aburunka-bah, which means "father of the knee," " 
scarlatinarheumatica," "eruptive articular fever," "eruptive rheumatic fever," "eruptive 
epidemic fever of India,"  " broken-wing fever," mudak-mariata, mudka  meaning contraction 
or stiffness, and mariata, the name of an idol or Hindoo deity (Smart, 1877, Thomas, 1880).  
Though sporadic prior to the World War II, the frequency of dengue outbreaks increased 
significantly after the war. It was accompanied by an increase in the incidence of 
complicated forms of dengue (DHF and DSS) in South East Asia (Halstead, 1966). Since 
then, there has been a worldwide surge in the number and severity of dengue cases. 
Currently, an estimated 50 million dengue infections occur annually and approximately 2.5 
billion people live in dengue endemic countries (WHO, 2009a). It is the most rapidly 
spreading mosquito-borne viral disease in the world and in the last 50 years its incidence 
has increased 30-fold with increasing geographic expansion to new countries. Besides 
making a comeback in places such as the Americas and Singapore, where dengue was 
previously successfully controlled for decades (Koh et al., 2008, Guzman and Kouri, 2003), it 
breached the subtropical temperate barrier and expanded from urban to rural settings 
extending its reach into places as far north as Nepal (Pandey et al., 2008), Ningbo China (Xu 
et al., 2007) and France (Gould et al., 2010); and as far south as Bueno Aires in Argentina 
(Natiello et al., 2008). The Pacific islands, with much lower population densities, have also 
not been spared, with increasing dengue outbreaks since the 1970s (Singh et al., 2005). 
Incidences in South East Asia and the Western Pacific account for greater than 75% of the 
global burden of dengue.  Within the Americas the burden of dengue accounts for 64.6% in 
the Southern Cone countries, 19% in the Andean contries, 12.5% in Central America and 
Mexico and 3.9% in the Caribbean (WHO 2009). In North America dengue is frequently seen 
in Texas and Hawaii (WHO 2009). Other regions in which dengue is endemic include the 
Eastern Mediterranean and the East and West African Regions (WHO, 2009). 
The increased intensity of dengue transmission is effected by the rise in number and size of 
densely populated urban cities, which are conducive for the spread of the disease and the 
adaptation and proliferation of dengue vectors; and by international travel  which results in 
the continuous importation  and exchange of dengue serotypes and genotypes that become 
established at various levels (Lee et al., 2010, Ng et al., 2009, Lambrechts et al., 2009). 
Although the efficiency of dengue virus transmission is affected by a complex interplay of 
multiple factors, the displacement of one genotype by another more “virulent” or “fit” type 
has been documented (Rico-Hesse, 2003). The epidemiology of dengue encephalitis and 
neurological dengue will therefore vary according to the interplay of virus virulence, 
transmissibility, host susceptibility, endemnicity and/or epidemic activity within 
geographic locations (Salazar et al., 2010). 
2.2 Incidence of dengue encephalitis 
Neurologic involvement occurs in 4%-5% of  confirmed dengue cases (Puccioni-Sohler et al., 
2009). The  incidence of dengue infection in patients with suspected central nervous system 
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(CNS) infection is noted to range from 4.2% in southern Vietnam (Solomon et al., 2000) to 
13.5% in Jamaica (Jackson et al., 2008). The higher frequency of neurological dengue (13.5%)  
reported by Jackson et al.,may be attributed to the inclusion of both adults and children in 
the study. In this study the frequency of dengue encephalitis among 401 patients with 
suspected viral central nervous system infections was found to be 6.9% (Jackson et.al., 
2008). The incidence of dengue among patients with clinical manifestations of 
encephalitis-like illness ranges from 18% (Kankirawatana et al., 2000) to 22% (Jackson et al., 
2008). Among confirmed neurological dengue cases studies have documented encephalitis 
to  be the presenting clinical manifestation in 52% (Jackson et al., 2008) to 56% (Solomon et 
al., 2000).. Other neurological manifestations of dengue noted in the Jamaican study include; 
meningits (34%), seizures (11%), acute flaccid paralysis and Guillain-Barré syndrome (4%).   
2.3 Transmission 
The transmission of DENV includes a sylvatic, enzootic cycle between nonhuman primates 
and arboreal mosquitoes of the genus Aedes, and an urban, endemic/epidemic cycle 
between human reservoir hosts and peridomestic Aedes spp., particularly mosquitoes with 
larval development in peridomestic water containers. Though the sylvatic dengue strains 
are associated with illness in Africa and Asia, they do not lead to sustained urban 
transmission. The Aedes (Stegomyia) aegypti (Egyptian tiger mosquito), a day-biting mosquito 
that is widespread along the tropical and subtropical belt, is the primary vector of the urban 
cycle. The Aedes (Stegomyia) albopictus, also known as the Asian tiger mosquito or forest day 
mosquito, is a secondary vector of dengue in Asia (Moncayo et al., 2004). In places such as 
China (including Hong Kong), Hawaii and France (Xu et al., 2007, Gould et al., 2010, Effler 
et al., 2005), where Ae. aegypti is absent, the Asian Tiger mosquito has been shown to be the 
vector of dengue transmission.  
Humans are the main amplifying host of the virus in the urban cycle.  DENV circulating in 
the blood of viraemic humans is ingested by female mosquitoes during feeding. The virus 
then infects the mosquito mid-gut and subsequently spreads systemically, including the 
salivary glands, over a period of 8-12 days. After this extrinsic incubation period, the virus 
can be transmitted to immunologically naive humans during subsequent probing or 
feeding. The extrinsic incubation period is influenced in part by environmental conditions, 
especially ambient temperature and the genetic make up of the virus. Thereafter the 
mosquito remains infective for the rest of its life. Ae. aegypti is one of the most efficient 
vectors for arboviruses because it is highly anthropophilic, frequently bites several times 
before completing oogenesis, and thrives in close proximity to humans. The eggs can remain 
viable for many months in the absence of water. Vertical transmission (transovarial 
transmission) of DENV has been documented  with infected eggs remaining viable for many 
months in the absence of water. Factors influencing virus transmission include 
environmental and climate factors related to vector distribution and proliferation, host-
pathogen interactions and population immunological factors.  
Evolution and  virus adaptation  have resulted in endemic DENV-2 strains  being more 
efficient than sylvatic strains at infecting the peridomestic DENV vectors Ae. aegypti and Ae. 
albopictus. Evolutionary DENV emergence events (DENV 1–4) suggest that adaptation of 
DENV to new vectors and hosts occurred repeatedly from 300 to 1,500 years ago in Asia or 
Oceania. Continued emergence of endemic DENV from sylvatic progenitor strains occurs in 
conjunction with the peridomestication of Aedes mosquitoes and virus adaptation to these 
anthropophilic vectors (Moncayo et al., 2004). 
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3. Dengue virus  
Dengue virus (DENV)  belongs to the Flavivirus genus of the family Flaviviridae. There are  
4 genetically and antigenically distinct serotypes,( DENV 1–4). Infection with one genotype 
confers life long immunity to the serotype, but only temporary immunity to the other three. 
The virus is non-enveloped, spherical with a diameter of 50nm containing multiple copies of 
three structural proteins, a host-derived membrane bilayer and a single copy of a positive-
sense, single-stranded RNA genome. The genome is cleaved by host and viral proteases in 
three structural proteins (capsid, prM, the precursor of membrane protein and envelope 
protein) and seven nonstructural proteins (NS).   
4. Clinical manifestations of Dengue 
4.1 Classification of Dengue disease spectrum  
The significant contribution of dengue virus (DENV) as an etiological agent of central 
nervous system infections is evidenced by studies documenting the prevalence of dengue 
encephalitis of 4.2 % to 13% in dengue endemic regions and during dengue epidemics 
respectively (Solomon et al., 2000; Jackson, 2008). The 1997 World Health Organization 
(WHO) classification of symptomatic DENV infections defined dengue as: 
i) undifferentiated fever, ii) dengue fever (DF), and iii) dengue haemorrhagic fever (DHF).  
In this classification system, DHF is further classified into four severity grades, with grades 
III and IV being defined as dengue shock syndrome (DSS). Plasma leakage with or without 
 
Dengue +/- warning signs Severe Dengue
 Severe plasma leakage 
leading to:
– Shock
– Fluid accumulation with 
respiratory distress
 Severe bleeding-
– as evaluated by the clinician
 Severe organ 
involvement:
– Liver ALT or AST>=1000
– CNS impaired consciousness
– Heart and other organs
without warning signs
1. Severe plasma leakage
2. Severe haemorrhage
3. Severe organ 
impairment
with 
warning signs 
Criteria for Dengue +/- warning signs Criteria for Severe Dengue  
Probable Dengue
 Live in/travel to endemic 
area, fever and two of the 
following criteria:
– Nausea/Vomiting
– Rash
– Aches and pains
– Torniquet test positive
– Leukopaenia
– Any warning sign
 Laboratory confirmed 
dengue
– important when no sign 
of plasma leakage
Warning Signs*
 Abdominal pain or tenderness
 Persistent vomiting
 Clinical fluid accumulation
 Mucosal bleed
 Lethargy or restlessness
 Liver enlargement >2cm
 Increase in haematocrit (HCT) 
with concurrent rapid  
decrease in platelet count 
*requiring strict observation and 
medical intervention
 
Fig. 1. WHO suggested dengue case classification and levels of severity, (WHO, 2009) 
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hemorrhage and thrombocytopenia  (platelet count  of less than 100,000mm3) are important 
criteria of DHF/DSS (WHO, 1997) and assist in differentiating DHF/DSS from other 
arboviral encephalitides.  Although this classification into DF/DHF/DSS continues to be 
widely used, changes in the epidemiology of dengue  and difficulties in the use of the 1997 
WHO classification (Deen et al., 2006), together with the increase in clinically severe dengue 
inclusive of neurological dengue resulted in the proposition of an adjusted case  
classification according to levels of severity by WHO in 2009 (WHO, 2009b).  
The suggested classification system divides dengue infection into patients with severe 
dengue and those with non-severe dengue.  Non-severe dengue is divided further into two 
subgroups -patients with warning signs and those without them (Figure 1).  The challenge 
in classification and clinical diagnosis of dengue is indeed reflected by the statement made 
by the Expert Consensus Groups in Latin America (Havana, Cuba, 2007), South-East Asia 
(Kuala Lumpur, Malaysia, 2007), and at WHO headquarters in Geneva, Switzerland in 2008: 
“Dengue is one disease entity with different clinical presentations and often with 
unpredictable clinical evolution and outcome” (WHO, 2009b). Nevertheless, the proposed 
2009 WHO classification acknowledges the evidence of research findings that dengue 
patients without warning signs may develop severe dengue and that central nervous system 
(CNS) impaired consciousness may be one of the presentations of severe dengue. 
4.2 Clinical manifestations of Dengue encephalitis 
Dengue encepahlitis is a severe form of dengue. Clinical manifestations of dengue 
encephalitis documented in early and present descriptions of the disease suggests that it is 
an infrequent but serious manifestation of dengue virus infection. It should be considered in 
the differential diagnosis of acute viral encephalitis in geographic regions in which dengue 
is known to occur. Patients with  Dengue encephalitis  may be at risk of developing 
complications of dengue haemorrhagic fever (Muzaffar et al., 2006) although some patients 
with encephalitis may not show any characteristic features of the disease (Solomon et al., 
2000). It is possible that earlier descriptons of encephalitis may have been referred to as 
encephalomyelopathy because of failed attempts to demonstrate direct invasion of the  
central nervous system by the dengue virus (Muzaffar et al., 2006, Varatharaj, 2010). 
Several forms of Dengue encephalitis have been described. These include focal-encephalitis, 
pan-encephalitis, acute disseminated encephalomyelitis and meningoencephalomyelitis. The 
onset of encephalitis is usually sudden with non-specific prodromal symptoms, which include 
myalgia, malaise, fever, vomiting and diarrhoea. Within a few days patients display headache, 
disorientation, depressed sensorium and seizures.  Other features which have been identified 
include frontal release signs, abnormal posturing, facial nerve palsy and tetraparesis. Isolated 
case reports describe more esoteric features ranging from altered sensation to hippocampal 
encephalitis presenting as amnesia (Varatharaj, 2010, Newman Dorland, 2003). 
5. Pathogenesis  
5.1 Virus entry and replication 
Though evidences for various mechanisms are emerging, there is no consensus on the 
pathogenesis of DENV. During the feeding of mosquitoes on humans, DENV is presumably 
injected into the bloodstream, with spillover in the epidermis and dermis, resulting in 
infection of keratinocytes and immature Langerhans cells (epidermal dendritic cells [DC]).  
Infected cells then migrate from site of infection to lymph nodes, where monocytes and 
macrophages are recruited, which become targets of infection (Martina et al., 2009). 
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The DENV envelope (E) glycoprotein is known to play a key role in the binding of the 
virions to cells, which is critical for infectivity (Anderson et al., 1992). The virus binds on the 
cell surface, via the E glycoprotein and viral receptors which may include heparan sulfate or 
the lectin Dendritic Cell-Specific Intercellular adhesion molecule-3- Grabbing Non-integrin 
(DC-SIGN) (Nielsen, 2009, Chen et al., 1997, Tassaneetrithep et al., 2003). The virus can also 
bind to cell surface immunoglobulin receptors in the presence of antibodies to the E 
glycoprotein or membrane precursor (pre-M) protein, (Morens, 1994). In mature dendritic 
cells, antibodies enhance dengue infection via Fc receptors.  
Following fusion of viral and cell membranes in acidified endocytic vesicles, the viral RNA 
enters the cytoplasm. The viral proteins are then translated directly from the viral RNA as a 
single polyprotein, which is cleaved to yield three structural and seven nonstructural 
proteins (Henchal and Putnak, 1990). Cleavage of several of the viral proteins requires a 
functional viral protease encoded by the nonstructural protein NS3. The nonstructural 
protein NS5 is the viral RNA-dependent RNA polymerase, which assembles with several 
other viral proteins and several host proteins to form the replication complex. The complex 
transcribes the viral RNA to produce negative-strand viral RNA, which serves as the 
template for the production of the viral genomic RNA. 
Viral protein and RNA synthesis occur predominantly in the cytoplasm of host cells. 
Replication begins within 15 hrs after infection. DENV replication does not significantly 
affect the metabolic function of the host cell as exemplified by normal levels of protein 
synthesis by the infected host cells (Noisakran and Perng, 2008). Replication of the virus 
results in amplification of infection and dissemination through the lymphatic system. As a 
result of this primary viremia, several cells of the mononuclear lineage, including blood-
derived monocytes , myeloid DC  and splenic and liver macrophages  are infected (Martina 
et al., 2009). DENV’s tropism for circulating mononuclear cells in blood and for cells 
residing in the spleen, lymph nodes, and bone marrow has been demonstrated in infected 
AG129 mice. Leukocytes also have been shown to be infected with DENV in experimentally 
infected nonhumans primates (Martina et al., 2009). 
Downstream of dendritic cells, T-cells become activated and generate cytokines associated 
with vascular leakage and shock in addition to activating effector cells. Both the virus and 
the antibodies are involved in release of complement and anaphylatoxins which can cause 
or exacerbate DHF/DSS. These systems are inextricable and strongly associated with 
dengue pathogenesis (Nielsen, 2009). It should be noted that during secondary infections 
with heterologous DENV, high concentrations of DENV-specific immunoglobulin G (IgG) 
will complex newly produced virus that adheres to and is taken up by mononuclear cells. 
Following infection, mononuclear cells predominantly die by apoptosis , while abortively 
infected or bystander DC are stimulated to produce the bulk of mediators that are involved 
in inflammatory and hemostatic responses of the host. In this regard, factors that influence 
the amount of target cells infected, and consequently the levels of viremia, may determine 
the ratio of different proinflammatory and anti-inflammatory cytokines, chemokines, and 
other mediators, as well as the way in which the inflammatory response affects the 
hemostatic system (Martina et al., 2009). 
5.2 Antibody response 
At or a few days prior to the onset of illness, the virus can be detected in serum, plasma, 
circulating blood cells and other tissues for 4–5 days  followed by the disappearance of  
DENV and antigens from the blood coincident with the appearance of specific antibodies. 
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The NS1 antigen may be detected in some patients for a few days after defervescence 
(WHO, 2009b, Pok et al., 2010). Antibody response to infection differs according to the past 
exposure of the host to dengue serotypes and/or other flaviviruses. Previously unexposed 
patients develop a primary response characterized by a slow increase of specific IgM 
antibodies between days 3 to 5 after the onset of illness. IgM levels peak about two weeks 
after the onset of symptoms and then decline generally to undetectable levels over 2–3 
months. Anti-dengue serum IgG is generally detectable at low titres at the end of the first 
week of illness, increasing slowly and remains detectable after several months, and probably 
even for life. During a secondary dengue infection (a dengue infection in a host that has 
previously been infected by a dengue virus, or sometimes after non-dengue flavivirus 
vaccination or infection), IgG antibody titres rise rapidly to high levels, even in the acute 
phase and persists for periods lasting from 10 months to life. IgM levels at early 
convalescent stage are significantly lower in secondary infections than in primary ones and 
may be undetectable in some cases (WHO, 2009b).  
5.3 Pathogenesis of severe Dengue 
The pathogenesis of severe dengue is not completely understood but is likely to be 
multifactorial (Martina et al., 2009). Secondary infections are considered as one of the risk 
factors for severe dengue disease (DHF/DSS) (Thein et al., 1997, Guzman et al., 1991, Guzman 
et al., 1990) and form the basis of the antibody-mediated pathogenesis or  antibody-dependent 
enhancement theory (Nielsen, 2009, Noisakran. & Perng, 2008, Martina et al., 2009 ). There 
have however  been reports on the absence of association between secondary dengue or 
circulation of multiple serotypes and DHF/DSS (Harris et al., 2000, Morens et al., 1986). It is 
believed that antibody-mediated enhancement of infection either results in a high viral load or 
represents the link to type 2 cytokine responses (Martina et al., 2009). 
Dengue cross-reactive T cells have been shown to  lose their cytolytic activity (Martina et 
al.,2009) and once primed during primary infection with one of the dengue serotype or a 
member of the Flavivirus family respond vigorously (memory T-cell responses) upon 
exposure to a second infection releasing massive amounts of proinflammatory cytokines, 
which induce vascular endothelial cell activation and are the likely cause of the capillary 
leak syndrome and  predispose to DHF and DSS (Noisakran and Perng, 2008). Involvements 
of the liver and endothelial cell lining of different organ systems are important factors in the 
pathogenesis of severe dengue. Vascular permeability is increased through mediators which 
promote the widening of adherens junctions. Disruption of vascular integrity and increase 
capillary fragility is also affected by; thrombocytopenia, platelet dysfunction and virus 
infection of the endothelial cells (Martine et al., 2009). 
High levels of complement activation products C3a and C5a can be found in the plasma 
accompanied by accelerated consumption and a marked reduction of the complement 
components in DHF/DSS the time of defervescence and onset of plasma leakage. In severe 
dengue, complement can be directly activated by the NS1 dengue antigen or via the binding of 
heterotypic antibodies to NS1 expressed on infected cells. Production of the C5b-C9 complex 
subsequently triggers cellular reactions and stimulates the production of inflammatory 
cytokines that are associated with development of DHF/DSS. (Martina et al., 2009) 
The virulence theory hypothesis states that certain dengue strains are responsible for more 
severe disease (Martina et al. 2009) with increased severity being associated with primary 
infection with DENV-1 followed by infection with DENV-2 or DENV-3. Intra-epidemic 
evolution of the virus has also been found to be responsible for increased severity of disease. 
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Hyperthermal factors, physical status of virus in viremic individuals, conditioning of 
neutralizing antibody assay in DENV infection, concept of vector transmission, serotype 
virulence, nutritional status and genetic attributes of the infected individual (Noisakran and 
Perng, 2008) are factors which have been associated with severe dengue (Martina et al. 2009). 
The mechanism by which the dengue virus enters into the central nervous system in severe 
and non-severe dengue is not clearly understood. It is hypothesized that the increased capillary 
permeability and the effects of the “cytokine storm” play a role in the neuropathology of 
dengue. This is evidenced by the finding of cerebral edema even in cases of benign dengue, 
and which may explain the origin of severe headaches (Chaturvedi et al., 1991). 
5.4 Pathogenesis of neurological Dengue 
5.4.1 Primary and secondary infections 
Several  studies have refered to a pan-tropic nature of the dengue virus with increased 
documentation of its neurtopism in recent years. One pathogenesis theory of neurological 
dengue proposes secondary and  systemic derangements as a cause. In such cases 
encephalopathy and not encephalitis is the primary manifestation. Although 
encephalopathy can exist in severe dengue as a result of multi-oragan involvement, there is 
a growing body of evidence in support of dengue neurotropism. This is evidenced by the 
documentation of neurological manifestations in both primary and secondary dengue 
infections (Cam et al., 2001, Hendarto and Hadinegoro, 1992, Solomon et al., 2000, Janssen et 
al., 1998, Thisyakorn et al., 1999). Several studies have also reported neurological 
manifestations as the presenting symptom of dengue infection (Pancharoen and Thisyakorn, 
2001, Solomon et al., 2000, Soares et al., 2008, 2010). 
5.4.2 Virus detection in the CNS  
The early onset of neurological signs and symptoms in the viremic phase suggests direct 
CNS invasion by DENV (Lum et al., 1996, Soares st al. 2006). Studies with mice models  have 
shown that with  the  intravenous inoculation of dengue Induced cytotoxic factor, there is 
transient compromise in the integrity of the blood brain barrier. This occurs in a dose-
dependent manner, allowing leakage of protein and erythrocytes (Chaturvedi et al., 1991). 
Infiltration by DENV infected macrophages have also been proposed as one of the 
mechanisms  of direct CNS invasion (Miagostovich et al., 1997). 
There have been several reports of detection of dengue specific immunoglobulin IgM via 
enzyme linked immunoassay and dengue RNA via real-time polymerase chain reaction (RT-
PCR) in the cerebrospinal fluid (Agarwal et al., 2009, Cam et al., 2001, Angibaud et al., 2001, 
Garcia-Rivera et al., 2009, Puccioni-Sohler et al., 2009, Thisyakorn et al., 1999). In addition 
studies have also supported the intrathecal synthesis of IgG  (Puccioni-Sohler et al., 2009, 
Soares et al., 2006). Direct infection of the central nervous system (CNS) by dengue has been 
documented thorough virus antigen detection  using immunoperoxidase stain in CNS 
biopsies in fatal encephalopathy cases with confirmed dengue infection (Miagostovich et al., 
1997, Nogueira et al., 2002) and in CNS biopsies in fatal cases which presented with  
encephalitis (Pancharoen and Thisyakorn, 2001, Thisyakorn et al., 1999). Although the 
detection of viral antigens  is not evidence of viral replication studies have identified  
dengue antigens in the neurons, astrocytes, microglia and Purkinje cells in autopsies and 
necropsies (Bhoopat et al., 1996, Ramos et al., 1998, Bordignon et al., 2008, Jessie et al., 2004).  
Encephalitis, apoptosis and CNS replication of dengue virus has also been observed in the 
neurons in the cortex and hippocampus following intracerebral inoculation  of  mice with 
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neuroadapted DENV1 viruses (Despres et al., 1998). Neuronal apoptosis has also been 
observed in fatal human DENV2 and DENV3 infections but the authors of the report 
attributed this to severe brain ischemia as dengue virus antigens were not detected via 
immunohistochemical staining in these cases (Limonta et al., 2007, Limonta et al., 2009). 
Immunostaining for NS3 of all dengue serotypes  has revealed the presence of dengue 
antigen in perivascular cells of the cerebrum   in interferon-receptor deficient mouse models 
infected with dengue and in fatal cases of human dengue infection (Balsitis et al., 2009). 
However in the study by Balsitis et al., none of the  fatal cases  presented with signs of 
neurological involvement thus demonstrating that DENV-infected cells may be present in 
the central nervous system even in patients without neurological manifestations who 
present  with classic DHF/DSS signs and symptoms (Balsitis et al., 2009). 
5.4.3 Serotypes  
Neurological manifestations have been documented to occur with all dengue serotypes 
(Kunishige et al., 2004, Ramos et al., 1998, Solomon et al., 2000), with more frequent 
identification of  serotype 2 and 3  (Lum et al., 1996, Garcia-Rivera et al., 2009, Hendarto and 
Hadinegoro, 1992, Solomon et al., 2000) and less frequently with serotype 4 ( Ramos et al., 
1998). However  in other serotype neurovirulence studies using parental and live attenuated 
DENV2 and DENVV3 in monkeys, specifically Macacafascicularis and Macacamulatta,  lesions  
were less frequently observed in the central nervous system and clinical manifestations were 
not severe (Angsubhakorn et al., 1986, Angsubhakorn et al., 1987, Angsubhakorn et al., 1994).   
5.4.4 Genetic diversity 
It is important to note that most studies on clinical manifestations center on DENV 
serotypes as the main subdivision, with limited consideration to the genetic diversity among 
viruses within a serotype (Rico-Hesse, 1990, Lanciotti et al., 1994, Lanciotti et al., 1997). 
Animal studies using mice have shown that DENV3 genotype I , can cause neurological 
disease clinically and histologically if intracerebrally inoculated while genotype III (P1-
64/2006) causes only asymptomatic disease with mild disease on histology (Ferreira et al., 
2010). Infection with DENV3 genotype I is associated with decreased leukocytosis, the 
detection of viable virus concentrations  in the brain and higher levels of interferon-gamma, 
interleukin-6 and monocyte chemoattractant protein 1 (Ferreira et al., 2010). The 
phenomenon that RNA viruses  are known to be of low fidelity, forming numerous variants 
called quasispecies (Clyde et al., 2006), has been observed in acute dengue infections 
(Lauring and Andino, 2010). 
5.4.5 Envelope protein  
Substitution of aspartate-67   for asparagine-67  in DENV envelope sequences is associated 
with a greater  electrostatically negative charge  and this substitution  has been identified in  
the sequences of viruses causing encephalitis (Barker et al., 2009). In contrast asparagine is 
found in the position corresponding to glycosylated asparagine-67 in DENV2, in all known 
flaviviruses causing hemorrhagic disease, and in 93% of sequences of viruses causing 
hemorrhagic fever . However, asparagine was only located in 33% (2/6) flaviviruses causing 
encephalitis and in 2.6% of the relevant encephalitic sequences (Barker et al., 2009). 
Different amino acid substitutions have been described (Bordignon et al., 2007) and studies 
on the other DENV serotypes have shown an association of amino acid substitutions in E 
protein domain with neurovirulence (Bray et al., 1998, Kawano et al., 1993, Lee et al., 1997). 
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Amino acid substitution of glutamate to lysine at position 126 in E protein domain II, has 
been shown to contribute to DENV2 neurovirulence in mice (Hiramatsu et al., 1996, Gualano 
et al., 1998). Substitutions at position 62 and 203 of domain II of DENV2 E protein were also 
reported to alter neurovirulence (Zhao et al., 2003). Another amino acid substitution which  
occurs is in the alpha-helical region E400-412. This region  participates in the conversion of E 
dimer to homotrimers and cellular attachment (Modis et al., 2004, Stiasny et al., 2005). 
The position of isoleucine-209 on  non-structural protein 3 (NS3) on domain 1 has been 
found  in association with all viruses causing encephalitis (Xu et al., 2005). One such amino 
acid substitution  observed in a study on mice neuroadapted DENV1, is valine-209 to 
isoleucine-209 (Bordignon et al., 2007). This  coincides with the NTPase domain of  DENV2 
(Xu et al., 2005). A second significant neurovirulent  amino acid substitution is observed in 
the NS3 domain II at position 435 (Bordignon et al., 2007, Despres et al., 1998) which 
corresponds to the beta-hairpin tip of the helicase domain  (Duarte dos Santos et al., 2000). 
5.4.6 Host factors 
Reserch studies indicate that genetic factors are improtant and play a role in population 
susceptibility and  disease severity (Martina et al., 2009). Host genetic predisposition has been 
proposed  to be a risk factor in presentations such as monophasic neuromyelitis optica (NMO), 
a rare form of post-infectious acute disseminated encephalomyelitis (ADEM) (Miranda de 
Sousa et al., 2006). Non-HLA and HLA-associated genetic factors implied as predisposing 
factors for severe dengue include; Vitamin D receptor polymorphism, glucose-6-phosphate 
dehydrogenase (G6PD) deficiency, mannose-binding lectin (MBL)2, Fc_RIIa  polymorphism, 
TNF-alpha (-308) A allele and IL-10 (-1082/-819/-592) ACC/ATA haplotype, CTLA- 4, 
transporters associated with antigen presentation and human platelet antigen, DC-SIGN 
polymorphism, HLA class I alleles A*01, A*0207, A*24, B*07, B*46, B*51  and  HLA class II 
alleles DQ*1, DR*1,  DR*4 (Martina et al., 2009). TNFalpha (-308) GG and TGFbeta1 (c25) GG 
genotypes have been shown to be associated with protection. 
5.4.7 Ancillary studies  
Ancillary investigations include lumbar puncture, neuroimaging and electroencephalogram 
(EEG). Lumbar puncture may be normal or may demonstrate pleocytosis with normal or 
mildly elevated protein and normal glucose (Muzaffar et al., 2006, Lum et al., 1996, Misra et 
al., 2006). 
Cerebral edema has been the primary finding of neuroimaging studies using computed 
tomography and magnetic resonance imaging (MRI).  In the prospective case control study 
by Cam and coworkers, MRI revealed cerebral edema (12/18) or no changes (4/18) in the 
majority of the patients with dengue encephalopathy, while only the minority (2/18) 
showed specifically scattered focal lesions (Cam et al., 2001,Muzaffar et al., 2006). EEG 
revealed slow background waves for the majority of the patients which resolves with 
clinical recovery (Angibaud et al., 2001, Arachchi et al., 2003, Lum et al., 1996, Misra et al., 
2006, Wasay et al., 2008). 
6. Laboratory diagnosis 
Early laboratory confirmation of clinical diagnosis may be valuable as some patients 
progress from mild to severe disease and sometimes to death, within a short period of time. 
Early intervention may be life-saving. Several laboratory methodologies are available for 
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confirming acute DENV infection and may be used singly or in combination. These include 
detection of the virus, viral nucleic acid, antigens and/or antibodies (Table 1). The hallmark 
for the laboratory diagnosis of encephalitis is the demonstration of the DENV or antigen in 
the tissues of the central nervous system and or the cerebrospinal fluid. 
 
Diagnostic Method Specimen
Time of collection after 
onset of symptoms
Diagnosis of acute 
infection
Virus isolation
Serotype confirmation
Whole blood, 
serum, Tissue 1 to 5 days Confirmed
Nucleic acid detection
Whole blood, 
serum, plasma, 
Tissue 1 to 5 days Confirmed
NS1 antigen detection
Serum
Tissue 1 to 6 days Confirmed
IgM ELISA -paired seroconversion
Serum, plasma, 
whole blood
Acute sera (1-5 days) 
Convalescent sera 
(>15 days) Confirmed
IgM ELISA-Single sera
Serum, plasma, 
whole blood >5 days Probable
IgM  rapid test
Serum, plasma, 
whole blood >5 days Probable
IgG single serum , HI titre>1280
Serum, plasma, 
whole blood >5 days Probable
IgG (paired sera) by ELISA, HI or 
Neutralization test (seroconversion or 
4 fold rise)
Serum, plasma, 
whole blood
Acute sera (1-5 days) 
Convalescent sera  (>15 
days) Confirmed  
Table 1. Summary of laboratory methods used in the diagnosis  of dengue infection 
Adapted from summary of operating characteristics and comparative costs of dengue 
diagnostic methods, and interpretation of dengue diagnostic tests from Dengue and Control 
(DENCO) and other studies  (WHO, 2009b, Pok et al., 2010). To distinguish primary and 
secondary dengue infections, IgM/IgG antibody ratios are now more commonly used than 
the haemagglutination-inhibition test (HI) (WHO 2009). 
7. Prognosis  
The reported morbidity and mortality due to dengue encephalitis itself is low with most 
survivors recovering fully (Cam et al., 2001, Angibaud et al., 2001, Pancharoen and 
Thisyakorn, 2001). Documented sequelae from encephalitis included weakness and 
spasticity (Pancharoen and Thisyakorn, 2001) and, spasms (Soares et al., 2006). Encephalitis 
accompanied by post-infectious neurological manifestations however may have a prolonged 
recovery. Residual weakness can occur in patients with nerve palsies (Chappuis et al., 2004). 
Post-infectious myelitis may complicate encephalomyelitis. Myletis patients can remain 
www.intechopen.com
 
Flavivirus Encephalitis 
 
82
symptomatic with urinary retention or spastic paraparesis (Puccioni-Sohler et al., 2009, 
Soares et al., 2006). Residual abnormalities in vision have been documented in cases of 
maculopathy, optic neuritis and neuropathy (Sanjay et al., 2008, Wen et al., 1989). The 
majority of deaths are associated with dengue hemorrhagic fever or dengue shock 
syndrome (DHF/DSS) and not with direct neurological involvement. Studies have 
documented an increase risk of developing DHF/DSS among patients with neurological 
dengue (Muzaffar et al., 2006 & Ramos et al., 1998). Infrequent  causes of death have been 
attributed to tonsillar herniation secondary to cerebral edema (Wasay et al., 2008) and 
pontine hemorrhage with no underlying systemic derangement (Janssen et al., 1998). 
8. Conclusion 
The resurgence of dengue in the Americas and Pacific regions has been accompanied by a 
corresponding increase in frequency of documentation of dengue encephalitis. Dengue 
encephalopathy and dengue encephalitis are two distinct manifestations of neurological 
dengue. Although not a primary clinical manifestation, dengue encephalitis is a form of severe 
dengue which infrequently may occur without co-existing features of DHF and DSS. As the 
clinical presentation of dengue encephalitis is similar to that of other encephalitides, the 
diagnosis of this entity may be easily misdiagnosed. Identification of other criteria of severe 
and non-severe dengue will assist in greater accuracy of diagnosis of dengue encephalitis. 
Mortality associated with dengue encephalitis has been frequently associated with features of 
DHF and DSS. Although advances in unveiling the pathogenesis of dengue have been made, 
continued research is needed to fully elucidate the pathogenesis of the complex interplay of 
immunological responses, virus characteristics and host predisposing factors.   
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